Richard Porter
Hoofd Techniek/Wetenschap/O&O bij UNIQURE N.V.
Vermogen: 164 419 $ op 31-05-2024
Actieve functies van Richard Porter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
UNIQURE N.V. | Hoofd Techniek/Wetenschap/O&O | 05-10-2023 | - |
Corporate Officer/Principal | 01-04-2022 | 05-10-2023 |
Loopbaan van Richard Porter
Eerdere bekende functies van Richard Porter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Therachon AG | Operationeel Directeur | 01-07-2016 | 01-07-2019 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Hoofd Techniek/Wetenschap/O&O | 01-03-2014 | 01-08-2016 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01-09-2011 | 01-02-2014 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Directeur/Bestuurslid | 01-11-2019 | - |
Algemeen Directeur | 01-11-2019 | - | |
Oprichter | 01-11-2019 | - |
Opleiding van Richard Porter
The University of Southampton | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 3 |
Zwitserland | 3 |
Frankrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
Therachon AG | |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Beurs
- Insiders
- Richard Porter
- Ervaring